Statement #26: Dupilumab (anti IL-4/13) is a Health Canada approved biologic for EoE and can be considered for disease (1) refractory to conventional treatments; or (2) those not tolerating conventional therapy; (3) and/or patients with currently approved concurrent severe allergic conditions. This evidence concerns the gene IL4 and eosinophilic esophagitis.